Last mentioned: Mar 24, 2026
FDA Modernization Act 2.0
President Biden signs legislation removing the requirement for animal testing for biosimilars and new drugs.
Hybrid Submission Standards
Expected formalization of regulatory pathways that prioritize NAM data over animal data for specific drug classes.
OOC Commercialization
Widespread adoption of organ-on-a-chip systems in early-stage pharmaceutical R&D for toxicity screening.
EU Regulatory Shift
The European Parliament and EMA accelerate roadmaps for the phase-out of animal use in regulatory testing.
The pharmaceutical industry is navigating a historic shift as the FDA Modernization Act 2.0 removes the mandate for animal testing in drug development. However, while technologies like organ-on-a-chip and AI offer higher human predictivity, they currently lack the systemic complexity required to fully replace animal models in late-stage safety assessments.
This page surfaces every story mentioning FDA across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |